Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing

Laura Kaertner, Michael B. Steinborn, Hannes Kettner, Meg J. Spriggs, Leor Roseman, Tobias Buchborn, Christopher Timmermann, Robin Carhart‐Harris

Scientific Reports · 2021 · 152 citations · 60 references

DOIFull text

Open access

Concepts

TL;DR

Psychedelic microdosing involves ingesting near‑threshold doses of classic psychedelics, and while anecdotal reports claim mood benefits, placebo‑controlled trials have not consistently supported these effects. The study used a prospective web‑based design, asking participants who planned weekly microdosing to complete surveys before, during, and after a four‑week test period. Among 81 participants, microdosing was associated with greater well‑being, emotional stability, lower anxiety and depression, and increased resilience, social connectedness, agreeableness, nature relatedness, and psychological flexibility, but baseline positive expectancy predicted these gains, underscoring a significant placebo response and cautioning against overstating therapeutic value.

Abstract

Psychedelic microdosing describes the ingestion of near-threshold perceptible doses of classic psychedelic substances. Anecdotal reports and observational studies suggest that microdosing may promote positive mood and well-being, but recent placebo-controlled studies failed to find compelling evidence for this. The present study collected web-based mental health and related data using a prospective (before, during and after) design. Individuals planning a weekly microdosing regimen completed surveys at strategic timepoints, spanning a core four-week test period. Eighty-one participants completed the primary study endpoint. Results revealed increased self-reported psychological well-being, emotional stability and reductions in state anxiety and depressive symptoms at the four-week primary endpoint, plus increases in psychological resilience, social connectedness, agreeableness, nature relatedness and aspects of psychological flexibility. However, positive expectancy scores at baseline predicted subsequent improvements in well-being, suggestive of a significant placebo response. This study highlights a role for positive expectancy in predicting positive outcomes following psychedelic microdosing and cautions against zealous inferences on its putative therapeutic value.

References

60